

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number
WO 02/12196 A2



- (51) International Patent Classification⁷: C07D 223/00 (74) Agents: DAVIS, Stephen, B. et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).
- (21) International Application Number: PCT/US01/22829
- (22) International Filing Date: 20 July 2001 (20.07.2001) (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 09/633,751 7 August 2000 (07.08.2000) US
- (71) Applicant (*for all designated States except US*): BRISTOL-MYERS SQUIBB COMPANY [US/US]; P.O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): BISACCHI, Gregory, S. [US/US]; 130 Mountain Road, Ringoes, NJ 08551 (US). SEILER, Steven, M. [US/US]; 101 North Main Street, Pennington, NJ 08534 (US). LAWRENCE, R., Michael [US/US]; 48 W. Crown Terrace, Yardley, PA 19067 (US). SUTTON, James, C., Jr. [US/US]; 8 Stonelea Drive, Princeton Junction, NJ 08550 (US). SLUSARCHYK, William, A. [US/US]; 19 Richmond Drive, Skillman, NJ 08558 (US). ZHAO, Guohua [US/US]; 56 York Drive, Princeton, NJ 08540 (US).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(54) Title: LACTAM COMPOUNDS AND THEIR USE AS INHIBITORS OF SERINE PROTEASES AND METHOD



(a)



(b)



(i)




(ii)

(57) Abstract: Lactam inhibitors are provided which have the structure (I), x is (a) or (b) wherein Y is O or S and R⁴ is (i), (ii) or R⁸ at least one of R¹ and R² is hydrogen, and R¹, R², R³, R⁵, R⁶, R⁷, and R⁸, are as defined herein. These compounds are inhibitors of tryptase and thus are useful in treating asthma. Methods for treating asthma and related diseases are also provided.

LACTAM COMPOUNDS AND THEIR USE AS INHIBITORS
OF SERINE PROTEASES AND METHOD


The present invention relates to lactam inhibitors
5 of tryptase, which are useful as anti-inflammatory agents particularly in the treatment of chronic asthma and related diseases.

In accordance with the present invention, novel
10 substituted lactam derivatives are provided which are inhibitors of serine proteases and have the structure I.




including pharmaceutically acceptable salts thereof and
15 all stereoisomers thereof, and prodrug esters thereof, wherein at least one of R¹ and R² is hydrogen and the other of R¹ and R² is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, aminoalkylaryl, aminocycloalkylalkyl, aminoalkyl, aminoalkylcycloalkyl,
20 heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl, all optionally substituted through available carbon atoms with 1, 2, 3
25 or 4 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy, arylalkoxy, arylalkoxy, arylazo, heteroarylalkyl,
30 heteroarylalkenyl, heteroaryloxy, hydroxy, nitro,

cyano, amino, substituted amino, alkylamino,
 dialkylamino, thiol, alkylthio, arylthio, heteroarylthio,
 arylthioalkyl, aminoalkyl, alkyloxycarbonylaminoalkyl,
 arylalkyloxycarbonylaminoalkyl, alkylcarbonyl,
 5 arylcarbonyl, arylaminocarbonyl, aminocarbonyl,
 alkynylaminocarbonyl, alkylaminocarbonyl,
 alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy,
 alkylcarbonylamino, arylcarbonylamino, arylsulfinyl,
 arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl,
 10 arylsulfonylamino, heteroarylcarbonylamino,
 heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl,
 or alkylsulfinyl;



15



R^3 is selected from alkyl, alkenyl, alkynyl, aryl,
 heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl,
 cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl,
 20 cycloalkenyl, cycloheteroalkyl, cycloalkenylalkyl,
 polycycloalkenyl, or polycycloalkenylalkyl; all
 optionally substituted through available carbon atoms
 with 1, 2, 3 or 4 groups selected from hydrogen, halo,
 alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl,
 25 cycloalkyl, cycloalkylalkyl, cycloheteroalkyl,
 cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl,
 arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy,
 aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxy,
 heteroarylalkyl, heteroarylalkenyl, heteroaryloxy,
 30 hydroxy, nitro, cyano, amino, substituted amino,
 alkylamino, dialkylamino, thiol, alkylthio, arylthio,
 heteroarylthio, arylthioalkyl, alkylcarbonyl,
 arylcarbonyl, arylaminocarbonyl, alkoxy carbonyl,

aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl,
alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy,
alkylcarbonylamino, arylcarbonylamino, arylsulfinyl,
arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl,
5 arylsulfonylamino, heteroarylcarbonylamino,
heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl,
or alkylsulfinyl;

R⁵ and R⁶ are the same or different and are
independently selected from alkyl, alkenyl, alkynyl,
10 aryl, heteroaryl, arylalkyl, heteroarylalkyl,
cycloalkyl, cycloalkylalkyl, polycycloalkyl,
polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl,
cycloalkenylalkyl, polycycloalkenyl,
polycycloalkenylalkyl, arylcarbonyl, alkylcarbonyl,
15 alkoxycarbonyl, aryloxycarbonyl, arylsulfonyl, or
alkylsulfonyl, or R⁵ and R⁶ can be taken with the
nitrogen to which they are attached to form a
cycloheteroalkyl ring; all optionally substituted through
available carbon atoms with 1, 2, 3 or 4 groups selected
20 from hydrogen, halo, alkyl, haloalkyl, alkoxy,
haloalkoxy, alkenyl, alkynyl, cycloalkyl,
cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl,
aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl,
arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo,
25 heteroaryloxo, heteroarylalkyl, heteroarylalkenyl,
heteroaryloxy, hydroxy, nitro, cyano, amino, substituted
amino, alkylamino, dialkylamino, thiol, alkylthio,
arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl,
arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl,
30 aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl,
alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy,
alkylcarbonylamino, arylcarbonylamino, arylsulfinyl,
arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl,
arylsulfonylamino, heteroarylcarbonylamino,
35 heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl,
or alkylsulfinyl;

R^7 and R^8 can be the same or different and are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl, all optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxy, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino, alkylamino, dialkylamino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl, arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl, arylsulfonylamino, heteroarylsulfonylamino, heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl, or alkylsulfinyl.

In preferred embodiments, where in the formula I compounds




and (1) R^1 and R^2 are independently alkyl, cycloalkyl, alkenyl, phenyl, benzyl, cyanoalkyl, alkoxycarbonylalkyl, or phenyl mono- or disubstituted with lower alkyl, cyano, hydroxy, dialkylamino, alkoxy, benzyloxy, alkylamino, alkoxycarbonyl, pyrrolidino, morpholino, halogen, alkyl substituted with one or more fluorines, then Y is S;

and (2) where X is $\begin{array}{c} \text{R}^4 - \text{C} - \\ \parallel \\ \text{O} \end{array}$ and R^4 is R^8 , then R^8 is other than alkyl substituted with hydroxyaminocarbonyl.


Thus, the compounds of formula I of the invention can have the following structural formulae:

5

IA




IB




10

IC



ID




15


Preferred are compounds of formula ID wherein one of R^1 and R^2 is hydrogen and Y is O .

More preferred are compounds of formula ID wherein R^1 is H and R^2 is aminoalkylaryl such as

20



and aminocycloalkylalkyl, such as
























, and y


is 0.

Preferred compounds of the invention have the structures

5







It will be appreciated that in compounds illustrated above and throughout, where a nitrogen is included with an apparent open valence, the nitrogen includes a hydrogen atom.

In addition, in accordance with the present invention, a method for treating and/or preventing medical conditions related to tryptase (such as asthma, chronic asthma or allergic rhinitis) is provided, wherein
5 a compound of formula I is administered in a therapeutically effective amount which inhibits tryptase.

The following definitions apply to the terms as used throughout this specification, unless otherwise
10 limited in specific instances.

Unless otherwise indicated, the term "lower alkyl", "alkyl" or "alk" as employed herein alone or as part of another group includes both straight and branched chain hydrocarbons, containing 1 to 40 carbons (in the
15 case of alkyl or alk), preferably 1 to 20 carbons, more preferably 1 to 12 carbons (in the case of lower alkyl), in the normal chain, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-
20 trimethylpentyl, nonyl, decyl, undecyl, dodecyl, the various additional branched chain isomers thereof, and the like as well as such groups including 1 to 4 substituents which may be any of the R^1 or the R^2 substituents set out herein.

25 Unless otherwise indicated, the term "cycloalkyl" as employed herein alone or as part of another group includes saturated or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, including monocyclicalkyl, bicyclicalkyl and
30 tricyclicalkyl, containing a total of 3 to 20 carbons forming the rings, preferably 4 to 12 carbons, forming the ring and which may be fused to one aromatic ring as described for aryl, which include cyclopropyl,

cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, cyclohexenyl,



5 any of which groups may be optionally substituted with 1 to 4 substituents which may be any of the R^1 groups, or the R^1 substituents set out herein.

The term "cycloalkenyl" as employed herein alone or as part of another group refers to cyclic hydrocarbons containing 5 to 20 carbons, preferably 6 to 12 carbons and 1 or 2 double bonds. Exemplary cycloalkenyl groups include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclohexadienyl, and cycloheptadienyl, which may be optionally substituted as defined for cycloalkyl.

The term "aryl" as employed herein alone or as part of another group refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl or naphthyl including 1-naphthyl and 2-naphthyl) and may optionally include one to three additional rings fused to a carbocyclic ring or a heterocyclic ring (such as aryl, cycloalkyl, heteroaryl or cycloheteroalkyl rings) and may be optionally substituted through available carbon atoms with 1, 2, or 3 groups selected from hydrogen, halo, haloalkyl, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl, trifluoromethoxy, alkynyl, cycloalkylalkyl, cycloalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, aminoalkyl, heteroaryl, arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy, arylthio, arylazo, heteroarylalkyl, heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino wherein the amino includes 1 or 2 substituents (which are alkyl, aryl or any of the other aryl compounds mentioned in the definitions), thiol, alkylthio, arylthio, heteroarylthio,

cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, cyclohexenyl,



- 5 any of which groups may be optionally substituted with 1 to 4 substituents which may be any of the R^1 groups, or the R^1 substituents set out herein.

The term "cycloalkenyl" as employed herein alone or as part of another group refers to cyclic hydrocarbons containing 5 to 20 carbons, preferably 6 to 12 carbons and 1 or 2 double bonds. Exemplary cycloalkenyl groups include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclohexadienyl, and cycloheptadienyl, which may be optionally substituted as defined for cycloalkyl.

The term "aryl" as employed herein alone or as part of another group refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl or naphthyl including 1-naphthyl and 2-naphthyl) and may optionally include one to three additional rings fused to a carbocyclic ring or a heterocyclic ring (such as aryl, cycloalkyl, heteroaryl or cycloheteroalkyl rings) and may be optionally substituted through available carbon atoms with 1, 2, or 3 groups selected from hydrogen, halo, haloalkyl, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl, trifluoromethoxy, alkynyl, cycloalkylalkyl, cycloalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, aminoalkyl, heteroaryl, arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy, arylthio, arylazo, heteroarylalkyl, heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino wherein the amino includes 1 or 2 substituents (which are alkyl, aryl or any of the other aryl compounds mentioned in the definitions), thiol, alkylthio, arylthio, heteroarylthio,

arylthioalkyl, alkoxyarylthio, alkylcarbonyl, arylcarbonyl, alkyl-aminocarbonyl, arylaminocarbonyl, alkoxy carbonyl, aminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, 5 arylsulfinyl, arylsulfinylalkyl, arylsulfonylamino or arylsulfon-aminocarbonyl or any of the R¹ groups or the R¹ substituents set out herein.

The term "aralkyl", "aryl-alkyl" or "aryllower alkyl" as used herein alone or as part of another group 10 refers to alkyl groups as discussed above having an aryl substituent, such as benzyl or phenethyl, or naphthylpropyl, or an aryl as defined above.

The term "lower alkoxy", "alkoxy", "aryloxy" or "aralkoxy" as employed herein alone or as part of another 15 group includes any of the above alkyl, aralkyl or aryl groups linked to an oxygen atom.

The term "amino" as employed herein alone or as part of another group may optionally be independently substituted with one or two substituents, which may be 20 the same or different, such as alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl or thioalkyl. These substituents may be further substituted with a carboxylic acid or any of the R¹ groups or R¹ substituents thereof 25 as set out above. In addition, the amino substituents may be taken together with the nitrogen atom to which they are attached to form 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, 4-thiamorpholinyl, 1-piperazinyl, 4-alkyl-1-piperazinyl, 4-arylalkyl-1-piperazinyl, 4-diarylalkyl-1-piperazinyl, 1-pyrrolidinyl, 1-piperidinyl, or 1-azepinyl, optionally substituted with alkyl, alkoxy, alkylthio, halo, trifluoromethyl or hydroxy.

35 The term "lower alkylthio", "alkylthio", "arylthio" or "aralkylthio" as employed herein alone or as part of

another group includes any of the above alkyl, aralkyl or aryl groups linked to a sulfur atom.

The term "lower alkylamino", "alkylamino", "arylamino", or "arylalkylamino" as employed herein alone
5 or as part of another group includes any of the above alkyl, aryl or arylalkyl groups linked to a nitrogen atom.

The term "acyl" as employed herein by itself or part of another group, as defined herein, refers to an
10 organic radical linked to a carbonyl $\left(\begin{smallmatrix} \text{O} \\ \parallel \\ \text{C} \end{smallmatrix} \right)$ group; examples of acyl groups include any of the R^1 groups attached to a carbonyl, such as alkanoyl, alkenoyl, aroyl, aralkanoyl, heteroaroyl, cycloalkanoyl, cycloheteroalkanoyl and the like.

15 The term "alkanoyl" as used herein alone or as part of another group refers to alkyl linked to a carbonyl group.

Unless otherwise indicated, the term "lower alkenyl" or "alkenyl" as used herein by itself or as part
20 of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 3 to 12 carbons, and more preferably 1 to 8 carbons in the normal chain, which include one to six double bonds in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl,
25 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 4,8,12-tetradecatrienyl, and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl,
30 alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, hydroxy, heteroaryl, cycloheteroalkyl, alkanoylamino, alkylamido, arylcarbonyl-amino, nitro, cyano, thiol, alkylthio or any of the R^1 groups, or the R^1 substituents set out herein.

35 Unless otherwise indicated, the term "lower alkynyl" or "alkynyl" as used herein by itself or as part of another group refers to straight or branched chain



radicals of 2 to 20 carbons, preferably 2 to 12 carbons and more preferably 2 to 8 carbons in the normal chain, which include one triple bond in the normal chain, such as 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonynyl, 4-decynyl, 3-undecynyl, 4-dodecynyl and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, heteroaryl, cycloheteroalkyl, hydroxy, alkanoylamino, alkylamido, arylcarbonylamino, nitro, cyano, thiol, and/or alkylthio, or any of the R^1 groups, or the R^1 substituents set out herein.


Where alkyl groups as defined above have single bonds for attachment to other groups at two different carbon atoms, they are termed "alkylene" groups and may optionally be substituted as defined above for "alkyl".

Where alkenyl groups as defined above and alkynyl groups as defined above, respectively, have single bonds for attachment at two different carbon atoms, they are termed "alkenylene groups" and "alkynylene groups", respectively, and may optionally be substituted as defined above for "alkenyl" and "alkynyl".

Suitable alkylene, alkenylene or alkynylene groups $(CH_2)_p$ (where, p is 1 to 8, preferably 1 to 5) (which may include alkylene, alkenylene or alkynylene groups) as defined herein, may optionally include 1, 2, or 3 substituents which include any of the R^1 groups, or the R^1 substituents set out herein.

Examples of alkylene, alkenylene and alkynylene include






The term "halogen" or "halo" as used herein alone or as part of another group refers to chlorine, bromine, fluorine, and iodine as well as CF_3 , with chlorine or fluorine being preferred.

The term "metal ion" refers to alkali metal ions such as sodium, potassium or lithium and alkaline earth metal ions such as magnesium and calcium, as well as zinc and aluminum.

The term "cycloheteroalkyl" as used herein alone or as part of another group refers to a 5-, 6- or 7-


membered saturated or partially unsaturated ring which includes 1 to 2 hetero atoms such as nitrogen, oxygen and/or sulfur, linked through a carbon atom or a heteroatom, where possible, optionally via the linker
 5 (CH₂)_p (which is defined above), such as




10

and the like. The above groups may include 1 to 4 substituents such as alkyl, halo, oxo and/or any of the R¹ groups, or the R¹ substituents set out herein. In
 15 addition, any of the above rings can be fused to a cycloalkyl, aryl, heteroaryl or cycloheteroalkyl ring.

The term "heteroaryl" as used herein alone or as part of another group refers to a 5- or 6- membered aromatic ring which includes 1, 2, 3 or 4 hetero atoms
 20 such as nitrogen, oxygen or sulfur, and such rings fused to an aryl, cycloalkyl, heteroaryl or cycloheteroalkyl ring (e.g. benzothiophenyl, indolyl), and includes possible N-oxides. The heteroaryl group may optionally include 1 to 4 substituents such as any of the R¹ groups
 25 or the R¹ substituents set out above. Examples of heteroaryl groups include the following:





5

and the like.

The term "cycloheteroalkylalkyl" as used herein alone or as part of another group refers to
 10 cycloheteroalkyl groups as defined above linked through a C atom or heteroatom to a $(CH_2)_p$ chain.

The term "heteroarylalkyl" or "heteroarylalkenyl" as used herein alone or as part of another group refers to a heteroaryl group as defined above linked through a C
 15 atom or heteroatom to a $-(CH_2)_p-$ chain, alkylene or alkenylene as defined above.

The term "polyhaloalkyl" as used herein refers to an "alkyl" group as defined above which includes from 2
 20 to 9, preferably from 2 to 5, halo substituents, such as F or Cl, preferably F, such as CF_3CH_2 , CF_3 or $CF_3CF_2CH_2$.

The term "polyhaloalkyloxy" as used herein refers to an "alkoxy" or "alkyloxy" group as defined above which includes from 2 to 9, preferably from 2 to 5, halo
 25 substituents, such as F or Cl, preferably F, such as CF_3CH_2O , CF_3O or $CF_3CF_2CH_2O$.

The compounds of formula I can be present as salts, in particular pharmaceutically acceptable salts. If the compounds of formula I have, for example, at least one basic center, they can form acid addition salts. These
5 are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid or a hydrohalic acid, with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted,
10 for example, by halogen, for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or
15 citric acid, such as amino acids, (for example aspartic or glutamic acid or lysine or arginine), or benzoic acid, or with organic sulfonic acids, such as (C₁-C₄)-alkyl- or aryl-sulfonic acids which are unsubstituted or substituted, for example by halogen, for example methane-
20 or p-toluene-sulfonic acid. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center. The compounds of formula I having at least one acid group (for example COOH) can also form salts with bases. Suitable salts
25 with bases are, for example, metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower
30 alkylamine, for example ethyl-, tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethyl-propylamine, or a mono-, di- or trihydroxy lower alkylamine, for example mono-, di- or triethanolamine. Corresponding internal salts may furthermore be formed.
35 Salts which are unsuitable for pharmaceutical uses but which can be employed, for example, for the isolation or

purification of free compounds I or their pharmaceutically acceptable salts, are also included.

Preferred salts of the compounds of formula I include monohydrochloride, hydrogensulfate,
5 methanesulfonate, phosphate or nitrate.

All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form. The compounds of the present invention can have asymmetric centers at any of
10 the carbon atoms including any one of the R substituents. Consequently, compounds of formula I can exist in enantiomeric or diastereomeric forms or in mixtures thereof. The processes for preparation can utilize racemates, enantiomers or diastereomers as starting
15 materials. When enantiomeric or diastereomeric products are prepared, they can be separated by conventional methods for example, chromatographic or fractional crystallization.


It should be understood that the present invention
20 includes prodrug forms of the compounds of formula I such as alkylesters of acids or any known prodrugs for lactam derivatives.

The compounds of the instant invention may, for example, be in the free or hydrate form, and may be
25 obtained by methods exemplified by the following descriptions.

The compounds of formula I may be prepared by the exemplary processes described in the following reaction schemes. Exemplary reagents and procedures for these
30 reactions appear hereinafter and in the working Examples.

Compounds of formula I of the invention can be prepared from the corresponding amine 1 by using the sequence of steps outlined in Scheme I set out below.

Reaction Scheme I



10


Reaction of amine 1 in an inert organic solvent such as dichloromethane, chloroform or tetrahydrofuran with reactant acid chloride 2, sulfonyl chloride 3, chloroformate 4 or carbamoylchloride 5, employing a molar ratio of reactant:amine 1 within the range from about 5:1 to about 1:5, optionally in the presence of an acid scavenger such as triethylamine, diisopropylethylamine,

15

pyridine, or polyvinylpyridine, forms compounds ID, IA, IC or IB of the invention.


Starting compound 1 can be prepared by methods known in the art as outlined in Reaction Scheme IA below.

Reaction Scheme 1A




Compound 1 is a novel compound provided that R¹ and R² are as defined herein, but excludes alkyl, alkenyl, aryl, arylalkyl, cycloalkyl or polycycloalkyl.

Compounds of formula I of the invention wherein



can be prepared from the corresponding acid 6 by using the sequence of steps outlined in Scheme II (Procedures A and B) set out below. ..

Reaction Scheme II



5 **Procedure A:** For amines where R¹ or R² contain additional basic nitrogens.

Procedure B: For amines where R¹ or R² contain no additional basic nitrogens.

10 In Procedure A (for amines where R¹ or R² contain additional basic nitrogens), a mixture of a solution of amine 21 in an inert organic solvent such as THF, methylenechloride or chloroform, a carbodiimide such as diisopropylcarbodiimide (DIC) and 7-aza-1-hydroxy-
15 benzotriazole (HOAt) is reacted with acid 20, employing a molar ratio of amine 21:acid 20 within the range from about 5:1 to about 1:5, preferably at about 1:1.1, to form a reaction mixture which is purified via an SCX column to separate out compound IB of the invention.

20 The DIC will be employed in a molar ratio to acid
20 within the range from about 5:1 to about 1:5,
preferably at about 1.6:1, and the HOAt will be employed
in a molar ratio acid 20 within the range from about 5:1
to about 1:5, preferably at about 1.6:1.

25 In Procedure B (for amines where R¹ and/or R² contain no additional basic nitrogens) a mixture of a solution of amine 21 in an inert organic solvent such as THF, methylenechloride or chloroform, ethyldimethylaminopropylcarbodiimide (EDAC) and
30 dimethylaminopyridine (DMAP) with acid 20, employing a molar ratio of amine 21:acid 20 within the range from about 5:1 to about 1:5, preferably at about 1.5:1, to


form a reaction mixture which is purified via a SCX column to separate out compound IB of the invention.

The EDAC will be employed in a molar ratio to acid 20 within the range from about 5:1 to about 1.5, preferably at about 1.5:1, and the DMAP will be employed in a molar ratio to acid 20 within the range from about 5:1 to about 1:5, preferably at about 1.5:1.

Starting compound 20 can be prepared by methods known in the art as outlined in Reaction Scheme IIA.


10

Reaction Scheme IIA




20

Compounds of formula I of the invention wherein



can be prepared from the corresponding amine 1 by using
5 the sequence of steps outlined in Scheme III set out below.


Reaction Scheme III




10

Reaction of amine 1 (in an inert organic solvent such as dichloromethane, chloroform or tetrahydrofuran) with reactant 30 or 31 employing a molar ratio of 30 or
15 31:amine 1 within the range of from about 5:1 to about 1:5, followed by treatment with aminomethylpolystyrene (32), affords the compound of the invention IB' or IB''.

Compounds of formula I of the invention wherein




can be prepared from the corresponding acid 29

29

using the sequence of steps outlined in Scheme IV set out
5 below:


Reaction Scheme IV




R^1 and/or R^2 can be neutral or may contain a basic nitrogen. When R^1 or R^2 contains a basic nitrogen, the nitrogen may optionally be protected, for example with a BOC group or Cbz group. The protecting group can then be
15 removed, for example, by treating with TFA in methylene chloride for removal of a BOC or Cbz protecting group.

Starting compound 29 can be prepared by methods as outlined in Reaction Scheme IVa


Reaction Scheme IVa



5 Alternatively, compounds of formula I of the invention wherein




10 can be prepared from the corresponding amine **1**




15 using the sequence of steps outline in Scheme V set out below.

Reaction Scheme V:



- 5 R^1 and/or R^2 can be neutral or may contain a basic nitrogen. When R^1 or R^2 in starting amine **1** contains a basic nitrogen, the nitrogen may optionally be protected, for example, with a BOC group. The protecting group can then be removed, for example, by treating with TFA in
- 10 methylene chloride for removal of a BOC protecting group, as outlined below in Reaction Scheme VA.

Reaction Scheme VA



15

- The novel compounds of formula I of the invention possess tryptase inhibition activity. This activity was confirmed using either isolated human skin tryptase or
- 20 recombinant human tryptase prepared from the human

recombinant beta-protryptase expressed by baculovirus in insect cells. The expressed beta-protryptase was purified using sequential immobilized heparin affinity resin followed by an immunoaffinity column using an anti-tryptase monoclonal antibody. The protryptase was activated by auto-catalytic removal of the N-terminal in the presence of dextran sulfate followed by dipeptidyl peptidase I (DPPI) removal of the two N-terminal amino acids to give the mature active enzyme (Sakai et al, J. Clin. Invest., 97, pages 988-995, 1996). Essentially equivalent results were obtained using isolated native enzyme or the activated expressed enzyme. The tryptase enzyme was maintained in 2M sodium chloride, 10 mM 4-morpholine-propanesulfonic acid, pH 6.8.

The assay procedure employed a 96 well microplate. To each well of the microplate (Nunc MaxiSorp), 250 μ l of assay buffer [containing low molecular weight heparin and tris (hydroxymethyl)aminomethane] was added followed by 2.0 μ l of the test compound in dimethylsulfoxide. The substrate (10 μ l) was then added to each well to give a final concentration of either 370 μ M benzoyl-arginine-*p*-nitroaniline (BAPNA) or 100 μ M benzyloxycarbonyl-glycine-proline-arginine-*p*-nitroaniline (CBz-Gly-Pro-Arg-pNA). Similar data was obtained using either substrate. The microplate was then shaken on a platform vortex mixer at a setting of 800 (Sarstedt TPM-2). After a total of three minutes incubation, 10 μ l of the working stock solution of tryptase (6.1 mM final tryptase concentration for use with BAPNA or 0.74 nM for use with CBz-Gly-Pro-Arg-pNA) was added to each well. The microplate was vortexed again for one minute and then incubated without shaking at room temperature for an additional 2 minutes. After this time the microplate was read on a microplate reader (Molecular Devices UV max) in the kinetic mode (405 nm wavelength) over twenty minutes at room temperature. To determine the compound concentration that inhibited half of the enzyme activity (IC_{50}), the

fraction of control activity (FCA) was plotted as a function of the inhibitor concentration and curve to fit $FCA/(1[I]/IC_{50})$. The IC_{50} for each compound was determined 2-4 times and the obtained values were averaged.

5 As a result of this tryptase activity, the compounds of formula I as well as a pharmaceutically acceptable salt thereof, are useful as anti-inflammatory agents particularly in the treatment and/or prevention of chronic asthma and may also be useful in treating and/or
10 preventing allergic rhinitis, inflammatory bowel disease, psoriasis, conjunctivitis, atopic dermatitis, rheumatoid arthritis, osteoarthritis, and other chronic inflammatory joint diseases, or diseases of joint cartilage destruction. Additionally, these compounds may be useful
15 in treating or preventing myocardial infarction, stroke, angina and other consequences of atherosclerotic plaque rupture. Additionally, these compounds may be useful for treating or preventing diabetic retinopathy, tumor growth and other consequences of angiogenesis. Additionally,
20 these compounds may be useful for treating or preventing fibrotic conditions, for example, fibrosis, scleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, neurofibromas and hypertrophic scars. Additionally these compounds may be useful for treating and/or preventing
25 diseases involving angiogenesis including, but not limited to, cancer.

The compounds of the present invention may be used in combination with β -adrenergic agonists such as albuterol, terbutaline, formoterol, salmeterol,
30 bitolterol, pilbuterol, or fenoterol, as well as with anticholinergics such as ipratropium bromide, anti-inflammatory corticosteroids such as beclomethasone, triamcinolone, budesonide, fluticasone, flunisolide or dexamethasone, and anti-inflammatory agents such as
35 cromolyn, nedocromil, theophylline, zileuton, zafirlukast, monteleukast and pranleukast, and/or hypolipodemic agents such as pravastatin, simvastatin,

atorvastatin, fluvastatin, cerivastatin, itavastatin
(pitavastatin, NK-104), or visastatin (or rosuvastatin).

The compounds of the invention can be administered orally or parenterally such as subcutaneously or
5 intravenously, as well as by inhalation and nasal application, rectally, transdermally, or sublingually to various mammalian species known to be subject to such maladies, e.g., humans, cats, dogs and the like in an effective amount within the dosage range of about 0.1 to
10 about 100 mg/kg, preferably about 0.2 to about 50 mg/kg and more preferably about 0.5 to about 25 mg/kg (or from about 1 to about 2500 mg, preferably from about 5 to about 2000 mg) on a regimen in single or 2 to 4 divided daily doses.

15 The active substance can be utilized in a composition such as tablet, capsule, solution or suspension or in other type carrier materials such as transdermal devices, iontophoretic devices, rectal suppositories, inhalant devices and the like. The
20 composition or carrier will contain about 5 to about 500 mg per unit of dosage of a compound or mixture of compounds of formulas I, IA., IB, IC and ID. They may be compounded in conventional matter with a physiologically acceptable vehicle or carrier, excipient, binder,
25 preservative, stabilizer, flavor, etc., as called for by accepted pharmaceutical practice.

The following abbreviations are employed hereinbefore and in the Examples:


30 Ph = phenyl
Bn = benzyl
t-Bu = tertiary butyl
Me = methyl
35 Et = ethyl
TMS = trimethylsilyl
TMSN₃ = trimethylsilyl azide
TBS = tert-butyldimethylsilyl
Fmoc = fluorenylmethoxycarbonyl
40 Boc = tert-butoxycarbonyl
Cbz = carbobenzyloxy or carbobenzoyloxy or benzyloxycarbonyl
THF = tetrahydrofuran

- Et₂O = diethyl ether
hex = hexanes
EtOAc = ethyl acetate
DMF = dimethyl formamide
5 MeOH = methanol
EtOH = ethanol
i-PrOH = isopropanol
DMSO = dimethyl sulfoxide
DME = 1,2 dimethoxyethane
10 EDC or DCE = 1,2 dichloroethane
HMPA = hexamethyl phosphoric triamide
HOAc or AcOH = acetic acid
TFA = trifluoroacetic acid
i-Pr₂NEt = diisopropylethylamine
15 Et₃N = triethylamine
NMM = N-methyl morpholine
DMAP = 4-dimethylaminopyridine
NaBH₄ = sodium borohydride
NaBH(OAc)₃ = sodium triacetoxyborohydride
20 DIBALH = diisobutyl aluminum hydride
DCM = 4-(dicyanomethylene)-2-methyl-6-(4-dimethylamino-
styryl)-4H-pyran
LiAlH₄ = lithium aluminum hydride
n-BuLi = n-butyllithium
25 Pd/C = palladium on carbon
PtO₂ = platinum oxide
KOH = potassium hydroxide
NaOH = sodium hydroxide
LiOH = lithium hydroxide
30 K₂CO₃ = potassium carbonate
NaHCO₃ = sodium bicarbonate
DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene
EDC (or EDC.HCl) or EDCI (or EDCI.HCl) or EDAC = 3-ethyl-
3'-(dimethylamino)propyl- carbodiimide hydrochloride (or
35 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride)
HOBT or HOBT.H₂O = 1-hydroxybenzotriazole hydrate
HOAT = 1-Hydroxy-7-azabenzotriazole
BOP reagent = benzotriazol-1-yloxy-tris (dimethylamino)
40 phosphonium hexafluorophosphate
NaN(TMS)₂ = sodium hexamethyldisilazide or sodium
bis(trimethylsilyl)amide
Ph₃P = triphenylphosphine
Pd(OAc)₂ = Palladium acetate
45 (Ph₃P)₄Pd⁰ = tetrakis triphenylphosphine palladium
DEAD = diethyl azodicarboxylate
DIAD = diisopropyl azodicarboxylate
Cbz-Cl = benzyl chloroformate
CAN = ceric ammonium nitrate
50 SAX = Strong Anion Exchanger
SCX = Strong Cation Exchanger
Ar = argon


- N₂ = nitrogen
min = minute(s)
h or hr = hour(s)
L = liter
- 5 mL = milliliter
μL = microliter
g = gram(s)
mg = milligram(s)
mol = moles
- 10 mmol = millimole(s)
meq = milliequivalent
RT = room temperature
sat or sat'd = saturated
aq. = aqueous
- 15 TLC = thin layer chromatography
HPLC = high performance liquid chromatography
LC/MS = high performance liquid chromatography/mass
spectrometry
MS or Mass Spec = mass spectrometry
- 20 NMR = nuclear magnetic resonance
mp = melting point

The following working Examples represent preferred embodiments of the present invention.


5

Example 1

A.




10




To a solution of (16.77 g, 73.6 mmol, 1.0 eq) in THF (400 mL) under a nitrogen atmosphere at -78°C was added LiHMDS (1.0 M in THF, 150 mL, 150 mmol, 2.04 eq) dropwise via an addition funnel over 10 minutes. The resulting mixture was stirred for an additional 10 minutes at -78°C, warmed to room temperature and stirred at room temperature for 1 hour. The reaction mixture was then cooled to -78°C and phenyl 2-bromoacetate (14 mL, 88.3 mmol, 1.2 eq) was added. The reaction mixture was warmed to room temperature and stirred for 18 hours. 1N KHSO₄ was added until the pH remained neutral. NaCl (~5 g) was added to the resulting bi-phasic solution. After the layers were mixed and allowed to separate, the upper THF layer was removed and set aside and the aqueous layer was extracted once with EtOAc. The combined THF and EtOAc extracts were dried over MgSO₄, filtered and concentrated. Purification by silica gel chromatography provided 21g of title compound (75.7%). MS: m/z 399 (M + Na)⁺.

B.




A solution of Part A compound (7.0 g, 18.59 mmol, 1.0 eq) in 4 M HCl in dioxane (25 mL) was stirred at room temperature for 1.5 hours. Solvents were removed and the residue was reconstituted in $\text{CH}_2\text{Cl}_2/\text{Et}_2\text{O}$ to give 6.0 g of an off-white precipitate. Re-crystallization from $\text{CH}_2\text{Cl}_2/\text{Et}_2\text{O}$ afforded 5.14 g (88%) of title compound as a white solid. MS: m/z 277 ($\text{M} + \text{H}$) $^+$.

C.




A solution of Part B compound (2.7 g, 8.63 mmol, 1 eq), EDC (1.98 g, 10.3 mmol, 1.2 eq), HOBT (1.40 g, 10.35 mmol, 1.2 eq) in CH_2Cl_2 (100 mL) at 0°C was treated with $i\text{Pr}_2\text{NEt}$ (6.0 mL, 34.5 mmol, 4 eq). The reaction mixture was brought to room temperature and 4-biphenylcarboxylic acid (2.05 g, 10.35 mmol, 1.2 eq) was added. The reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was then diluted with CH_2Cl_2 , washed with 5% NaHCO_3 , dried over MgSO_4 , filtered and concentrated. Purification by silica gel chromatography gave 2.16 g (55%) of title compound as a white foam. MS: m/z 479 ($\text{M} + \text{Na}$) $^+$.

D.



To a solution of Part C compound (4.5 g, 9.86 mmol, 1.0 eq) in THF (200 mL) at RT was added 10%Pd/C (3 g) followed by bubbling of H₂ through the solution for 1 hour. The reaction was then stirred under H₂ for 4 hours. The reaction mixture was filtered through a pad of celite and the pad was rinsed twice with THF (2x25 mL). Solvent was removed to provide 3.62 g (100%) of title compound as a white solid. MS: m/z 367 (M +H)⁺.

10 E.




Part E compound was prepared as part of a semi-automated parallel library.

15 To a 16x100 mm reaction tube was added Part D compound (30 mg, 0.082 mmol, 1.0 eq), polystyrene-EDC (Advanced Chemtech catalog #SP5005, 100 mg, 0.8 mmol/g, 0.08 mmol, 0.98 eq), iPr₂NEt (0.05 mL, 0.29 mmol, 3.5 eq)


and amine
Nc1ccc(cc1)CN(C(=O)OC(C)(C)C)C (14 mg, 0.063 mmol, 0.77 eq) in DMF (0.6 mL) and DCE (1.0 mL), and was shaken for 3 days. Additional polystyrene-EDC (50 mg, 0.8 mmol/g, 0.04 mmol, 0.49 eq) and DCE (0.5 mL) were added and the reaction mixture was shaken for an additional 24 hours. To the reaction mixture was added Polystyrene-Trisamine (Argonaut Tech, 50 mg, 6.8 mmol/g, 0.34 mmol, 4.15 eq) as a scavenger resin and the reaction mixture was shaken for 24 hours. The reaction mixture was filtered and the eluent was concentrated using a speed vac. Purification by reverse phase preparative HPLC (Shimadzu VP-ODS, flow rate 20 mL/min) followed by concentration using a speed vac gave analytically pure title compound. MS: m/z 593 (M+Na)⁺.

F.



For compounds from the above semi-automated
 5 parallel library having BOC protecting groups,
 deprotection was carried out using the following
 procedure.

Part E compound was taken up in 10% TFA in DCE (5
 mL) and let set for 2 hours. Concentration using a speed
 10 vac then afforded 4.8 mg (10% from Part D compound) of
 title compound. MS: m/z 471 (M +H)⁺.

Example 2

15

A.




20

The title compound is a known compound as disclosed
 in Skiles, J.W., et al, Bioorg. Med. Chem. Lett., 1993,
 3, 773.

B.

3-Boc-aminomethyl aniline


25



The title compound is a known compound as disclosed
 in Collins, J.L., et al, J. Med. Chem., 1998, 41, 2858.


30

C.



TFA (20 mL) was slowly added to a solution of Part
 5 A compound (8.64 g, 22.95 mmol) in CH₂Cl₂ (30 mL) at 0°C.
 The reaction mixture was then stirred at room temp. After
 24 h the solution was concentrated. The residue was
 dissolved in CHCl₃ (50 mL) and the solution was
 concentrated. This was repeated 2 more times. A portion
 10 of the crude product was purified by silica gel
 chromatography giving 2.90 g of title compound.


D.



15

EDAC-HCl (1.74 g, 9.05 mmol) was added to a stirred
 solution of Part B compound (2.01g, 9.05 mmol), Part C
 compound (2.90 g, 9.05 mmol) and HOBT (1.22 g, 9.05 mmol)
 in CH₂Cl₂ (35 mL) at 0°C. NMM (1.04 mL, 9.50 mmol) was
 20 added and the reaction mixture was stirred at room temp.
 After 24 h the solution was diluted with CH₂Cl₂ (100 mL)
 and washed with 5% KHSO₄ (50 mL), sat. NaHCO₃ (50 mL), and
 sat NaCl (50 mL). The solution was dried (MgSO₄) and
 concentrated. The crude product was purified by silica
 25 gel chromatography to afford 3.60 g (78%) of title
 compound.


E.




30

20% Pd(OH)₂ (0.34 g) was added to a stirred
 solution of Part D compound (3.39g, 6.65 mmol) in MeOH
 (25 mL). A H₂ atmosphere was introduced via balloon. After
 24 h the solution was filtered and the filtrate was
 35 concentrated to give 2.44 g (94%) of title compound.


F.



5 To a reaction tube was added via liquid handler 320 μ L (10.8 mg, 0.048 mmol) of a 0.15 M stock solution of



in DMF. 0.30 mL of a DCE solution containing EDC (10.5 mg, 0.055 mmol) and DMAP (6.7 mg, 0.055 mmol) was added manually via syringe. 0.30 mL of a DCE solution containing Part E compound (18.8 mg, 0.050 mmol) was added via the liquid handler. The reaction tube was mixed on an orbital shaker for 12 h. The reaction mixture was then drained through a SCX cation exchange column (0.30 g of absorbent) which was preconditioned with MeOH (0.30 mL) into a 2.5 mL microtube. The column was rinsed with CH_2Cl_2 (0.30 mL) and MeOH (0.40 mL). The organic solution containing intermediate F(1)




was concentrated by speed vac.

DCE (0.60 mL) was added to the 2.5 mL microtube containing the above intermediate F(1). Upon dissolution TFA (0.30 mL) was added via syringe. The microtube was sealed and shaken using a mini-vortexer. After 3 h the solution was concentrated by speed vac. The product was dissolved in MeOH (1.0 mL) and purified via solid phase extraction using a SCX cation exchange column (0.30 g of absorbent) which was preconditioned with MeOH (0.30 mL). The column was washed with MeOH (2 x 1.5 mL) to remove impurities. The product was then eluted off the column using 2.0 M NH_3 in MeOH (1.5 mL). The eluant was then concentrated by speed vac. The crude product was further purified by PREP HPLC (Shimadzu VP-ODS 20 x 50 mm column) using a gradient of 0 to 100% Solvent B over 5 min and a

flow rate of 20 mL/min. 6.73 mg (23%) of title compound was obtained. Mass spec $(M+H)^+ = \text{calc'd} = 499$, found = 499.

5

Example 3

Solution A: To a solution of Example 1 Part D compound (240 mg, 0.655 mmol) in dichloroethane (15 ml) was added DMAP (199 mg, 1.63 mmol) followed by EDC (251 mg, 1.31 mmol). Dichloroethane was added to bring the total volume to 18 ml. This reaction mixture was stirred at room temperature for 2 hours.








To a 16x100 mm reaction tube containing N-BOC-1,5-diaminopentane (33 mg, 0.164 mmol) was added Solution A (2 ml, 0.073 mmol of Example 60 Part D compound). The reaction tube was capped and warmed to 40°C for 20 hours. The reaction was cooled to room temperature and was then passed through an SCX cartridge (CUBCX12M6). The SCX cartridge was washed with methanol (8 ml) and the eluent was collected. Solvents were removed using a speed vac and the resulting residue was taken up in 30% TFA/dichloroethane (2 ml). After agitating the TFA/dichloroethane solution for 2 hours at room temperature, solvents were removed using a speed vac to afford 19 mg (46%) of title compound. MS: m/z 451.21 $(M+H)^+$.

30


Examples 4 to 103

The following compounds were prepared employing procedures as described in previous Examples.

5


Example No	Structure	Mass Spec. m/z (M+H) ⁺
4		466
5		485
6		471
7		485
8		477
9		557
10		454

11




471

12




503

13




507

14




495

15




484

16




468

17




482

18




583

19




425

20




485

21




506

22




501

23




477

24




551

25




475

26




451

27




465

28




466

29




499

30




497

31




511

32




501

33




481

34




487

35




555

36




495

37




451

38




465

39




471

40




478

41




596

42




435

43



494

44



446

NEW ZEALAND

=====

PATENTS ACT, 1953

=====

**REQUEST FOR POSTPONEMENT OF ACCEPTANCE OF COMPLETE
SPECIFICATION [SECTION 20(1A)]**

=====

We, QLT Inc., hereby request a postponement of the acceptance of the complete specification of the attached request for entry into the National Phase in New Zealand, to a date not later than the expiration of 15 months from the date on which we fulfil our obligation under Article 22(1) or Article 39(1) of the Patent Cooperation Treaty.

DATED this seventh Day of September, 2005


QLT Inc.
By Attorneys for the Applicant
SPRUSON & FERGUSON

Per:

THE COMMISSIONER OF PATENTS
INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND
LOWER HUTT


Fee: N/A

45




487

46




473

47




477

48




437

49




487

50




425

51




489

52




485

53




489

54




540

55



499

56



471

NEW ZEALAND

PATENTS ACT, 1953

**NOTICE OF DESIRE FOR EXTENSION OF THE PERIOD FOR PUTTING
AN APPLICATION IN ORDER**

We, QLT Inc., hereby give notice that we desire the period for putting in order application No. 533036 dated 8 November 2002 to be extended to 3 months from the filing date of the complete specification to 24 December 2005.

Our address for service is as follows:

SPRUSON & FERGUSON
PO Box 30461
Lower Hutt
NEW ZEALAND


DATED this seventh Day of September, 2005

QLT Inc.
By Attorneys for the Applicant
SPRUSON & FERGUSON

Per:


THE COMMISSIONER OF PATENTS
INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND
LOWER HUTT

57




559

58




482

59




508

60




471

61




461

62




511

63




544

64




497

65




522

66




514

67




475

68




485

69




466

70




453

71




463

72




501

73




489

74




490

75




439

76




465

77




439

78




423

79




477

80




477

81




453

82




415

83




429

84




581

85




411

86




410

87




451

88




464

89




455

90




501

91




425

92




429

93




439

94




452

95




502

96




423

97




429

98




439

99




473

100




452

101




463

102




522

103




501

1. A compound having the formula



and a pharmaceutically acceptable salt thereof and all
 5 stereoisomers thereof, and prodrug esters thereof,
 wherein

at least one of R¹ and R² is hydrogen and the other
 of R¹ and R² is selected from hydrogen, alkyl, alkenyl,
 alkynyl, aryl, aminoalkylaryl, aminocycloalkylalkyl,
 10 aminoalkyl, aminoalkylcycloalkyl, heteroaryl, arylalkyl,
 heteroarylalkyl, cycloalkyl, cycloalkylalkyl,
 polycycloalkyl, polycycloalkylalkyl, cycloalkenyl,
 cycloheteroalkyl, cycloalkenylalkyl, polycycloalkenyl, or
 polycycloalkenylalkyl; all optionally substituted through
 15 available carbon atoms with 1, 2, 3 or 4 groups selected
 from hydrogen, halo, alkyl, haloalkyl, alkoxy,
 haloalkoxy, alkenyl, alkynyl, cycloalkyl,
 cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl,
 aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl,
 20 arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo,
 heteroarylalkyl, heteroarylalkenyl, heteroaryloxy,
 hydroxy, nitro, cyano, amino, substituted amino,
 alkylamino, dialkylamino, thiol, alkylthio, arylthio,
 heteroarylthio, arylthioalkyl, aminoalkyl,
 25 alkyloxycarbonylaminoalkyl, arylalkyloxycarbonyl-
 aminoalkyl, alkylcarbonyl, arylcarbonyl,
 arylaminocarbonyl, aminocarbonyl, alkynylaminocarbonyl,
 alkylaminocarbonyl, alkenylaminocarbonyl,
 alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino,
 30 arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl,
 arylsulfonyl, alkylsulfonyl, arylsulfonylamino,
 heteroarylcarbonylamino, heteroarylsulfinyl,
 heteroarylthio, heteroarylsulfonyl, or alkylsulfinyl;



R³ is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl, cycloalkenylalkyl, polycycloalkenyl, or polycycloalkenylalkyl; all optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxy, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino, alkylamino, dialkylamino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl, arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl, arylsulfonylamino, heteroarylcarbonylamino, heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl, or alkylsulfinyl;


R⁵ and R⁶ are the same or different and are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl, arylcarbonyl, alkylcarbonyl, alkoxycarbonyl, aryloxy, arylsulfonyl, or alkylsulfonyl, or R⁵ and R⁶ can be taken with the

nitrogen to which they are attached to form a cycloheteroalkyl ring; all optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxo, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino, alkylamino, dialkylamino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl, arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl, arylsulfonylamino, heteroarylsulfonylamino, heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl, or alkylsulfinyl;

R⁷ and R⁸ are the same or different and are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl, all optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxo, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino, alkylamino, dialkylamino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl,

arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl,
 aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl,
 alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy,
 alkylcarbonylamino, arylcarbonylamino, arylsulfinyl,
 5 arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl,
 arylsulfonylamino, heteroarylcarbonylamino,
 heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl,
 or alkylsulfinyl.


- 10 2. The compound as defined in Claim 1 where
 (1)




- and R¹ and R² are independently cycloalkyl, alkenyl,
 phenyl, benzyl, cyanoalkyl, alkoxycarbonylalkyl, or
 15 phenyl mono- or disubstituted with lower alkyl, cyano,
 hydroxy, dialkylamino, alkoxy, benzyloxy, alkylamino,
 alkoxycarbonyl, pyrrolidino, morpholino, halogen, alkyl
 substituted with one or more fluorines, then Y is S; and

- 20 (2) where X is $\begin{array}{c} \text{R}^4 - \text{C} - \\ \parallel \\ \text{O} \end{array}$ and R⁴ is R⁸, then R⁸ is
 other than alkyl substituted with hydroxyaminocarbonyl.


3. The compound as defined in Claim 1 having the
 formula




- 25 4. The compound as defined in Claim 1 having the
 formula



5. The compound as defined in Claim 1 having the formula




6. The compound as defined in Claim 1 having the formula




7. The compound as defined in Claim 6 wherein one of R¹ and R² is hydrogen and the other is aminoalkylaryl or aminocycloalkylalkyl, and y is 0.


8. The compound as defined in Claim 7 wherein one of R¹ and R² is




and Y is O.

9. The compound as defined in Claim 1 having the structure





10. A compound having the structure



- 5 wherein R^1 and R^2 are the same or different and are independently selected from hydrogen, alkynyl, heteroaryl, aminoalkylaryl, aminocycloalkylalkyl, aminoalkyl, aminoalkylcycloalkyl, heteroarylalkyl, cycloalkenyl, cycloheteroalkyl, heteroaryloxy, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenyl-alkyl, or R^1 and R^2 can be taken with the nitrogen to which they are attached to form a cycloheteroalkyl ring; all optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxy, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino, alkylamino, dialkylamino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, aminoalkyl, alkyloxycarbonylaminoalkyl, arylalkyloxycarbonyl-aminoalkyl, alkylcarbonyl, arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy,
- 10
15
20
25

alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl, arylsulfonylamino, heteroarylcarbonylamino, heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl, 5 alkylsulfinyl; or a pharmaceutically acceptable salt thereof, with the proviso that at least one of R¹ and R² is hydrogen.

11. A pharmaceutical composition comprising a 10 compound as defined in Claim 1 and a pharmaceutically acceptable carrier therefor.

12. Use of a compound as defined in Claim 1 for the preparation of a pharmaceutical composition for 15 inhibiting a serine protease, for treating and/or preventing inflammation, asthma, or allergic rhinitis, for treating and/or preventing medical conditions in a mammalian species related to tryptase, for treating and/or preventing inflammatory bowel disease, psoriasis, 20 conjunctivitis, atopic dermatitis, rheumatoid arthritis, osteoarthritis, chronic inflammatory joint disease, diseases of joint cartilage destruction, treating and/or preventing myocardial infarction, stroke, angina, diabetic retinopathy, diseases involving angiogenesis, 25 tumor growth, cancer, fibrosis, scleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, neurofibromas and/or hypertrophic scars.

13. A pharmaceutical combination comprising a 30 compound as defined in Claim 1 in combination with a hypolipidemic agent, a β -adrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid or an anti-inflammatory agent.

14. The pharmaceutical combination as defined in Claim 13 wherein the β -adrenergic agonist is albuterol, terbutaline, formoterol, fenoterol, salmeterol, bitolterol, or pilbuterol, and the anti-inflammatory agent is beclomethasone, triamcinolone, flurisolide, dexamethasone, budesonide, fluticasone, cromolyn, nedocromil, theophylline, zileuton, zafirleukast, monteleukast and pranleukast, and wherein the hypolipodemic agent is pravastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, rosuvastatin or itavastatin.